Literature DB >> 16282309

Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only?

Miro Morovic1.   

Abstract

Medical records of 77 patients with Q fever pneumonia that was serologically confirmed by enzyme-linked immunosorbent assay were studied to compare the clinical efficacy of doxycycline, clarithromycin, and moxifloxacin. The mean times to defervescence were 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin. There were no interruptions of the regimens in any groups because of side effects, and outcome was favorable in all patients with no complications or relapses during follow-up. This efficacy of clarithromycin and moxifloxacin, together with their safety profiles, suggest that these alternative agents in the treatment of Q fever pneumonia could also be used as the first-line therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282309

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

Review 1.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

2.  Differentiation of Acute Q Fever from Other Infections in Patients Presenting to Hospitals, the Netherlands

Authors:  Stephan P Keijmel; Elmer Krijger; Corine E Delsing; Tom Sprong; Marrigje H Nabuurs-Franssen; Chantal P Bleeker-Rovers
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

3.  Coxiella burnetii in humans, domestic ruminants, and ticks in rural western Kenya.

Authors:  Darryn L Knobel; Alice N Maina; Sally J Cutler; Eric Ogola; Daniel R Feikin; Muthoni Junghae; Jo E B Halliday; Allen L Richards; Robert F Breiman; Sarah Cleaveland; M Kariuki Njenga
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

4.  Doxycycline desensitization in chronic Q fever-A critical tool for the clinician.

Authors:  Aila Luise Caplunik-Pratsch; Israel Potasman; Aharon Kessel; Alona Paz
Journal:  IDCases       Date:  2018-02-20

5.  Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.

Authors:  Marissa S Fullerton; Punsiri M Colonne; Amanda L Dragan; Katelynn R Brann; Richard C Kurten; Daniel E Voth
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.